2018 - PRESS RELEASES

First Duchenne Patient Dosed in Microdystrophin Gene Therapy! - January 10th 2018

Young Boy Becomes First DMD Patient to Receive Investigational Systemic Microdystrophin Gene Therapy  - January 19th 2018

MDA Clinical Conference Keynote Adress by Dr. Jerry Mendell - March 2018

 How Myonexus Therapeutics is developing the first treatment for Limb Girdle Muscular Dystrophies - March 29th 2018

Myonexus Therapeutics receives FDA orphan drug designation for LGMD type 2E treatment

Pioneering, corrective gene therapies have potential to transform quality of life  April 2018

Limb Girdle Muscular Dystrophy Type 2E Recruitment Study - Pubmed.gov -  April 10th 2018

Clinical Research Forum Top Ten Clinical Research Achivement Awards  - April 17th 2018 

Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies May 3th 2018

Myonexus  Therapeutics receives  FDA  Rare Pediatric Disease Designation  May 2018

 Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D  (LGMD2D) – PubMed.gov - June 2018

Positive preliminary results from the first three children dosed in phase 1/2A gene Therapy micro-dystrophin trial – Parent Project - June 19th 2018 

MDA Funds Creation of Limb-Girdle Muscular Dystrophy Clinical Research Network to Speed Therapy Development  -  July 27th 2018

Myonexus Therapeutics announced the initiation of a trial for the first-ever Gene Therapy for  Beta-Sarcoglycanopathy -   2018

Atrofia Muscolare Spinale: a luglio avvio in Italia sperimentazione di terapia genica. 

Our vision for the future of Precision Genetic Medicine - Sarepta Therapeutics 2018 R&D Day

Clinical Update: Micro-dystrophin Study-101 – Sarepta  - 2018